top of page
Screenshot 2024-01-30 163313.png

OncoBLAZE

Reimagining Precision Cancer Therapy

OncoBLAZE logo_green DALL-E_v3_transpare

Cancer Recurrence

Cancer recurrence refers to the return of cancer following treatment after a period of remission or apparent eradication. It indicates that cancer cells have survived initial treatment and have begun to grow again, potentially in the same location or elsewhere in the body.

Screenshot 2024-01-30 160102.png

Cancer rates are expected to increase to 28.4 million annual cases globally by 2040 and cancer recurrence will not only impact individuals but also pose a significant economic burden due to additional treatments and increased healthcare utilization. Despite the efficacy of surgery as a treatment modality, specific cancers such as Soft Tissue Sarcoma, Oral Cavity Cancer, Head and Neck Cancer, and Pancreatic Cancer present unique challenges in achieving complete eradication of malignant cells. Consequently, residual cancer cells pose a persistent risk of recurrence.

Screenshot 2024-01-30 161837.png

Our Mission

At OncoBLAZE, we aim to develop innovative technologies that deliver therapy precisely to cancer cells that remain after surgery. We are committed to improving patient outcomes and reducing the burden of cancer recurrence. Our mission drives us to continuously innovate and collaborate with stakeholders to address unmet needs in cancer care, ultimately striving for a future where every patient receives personalized and effective treatment.

Our Technology

Our technology aims to deliver a potent chemotherapy dose with precise targeting to remnant cancer cells. After surgery, triggered nanoparticles (TNP) encapsulating a chemotherapeutic are administered to the patient and distributed throughout the body. As long as the chemotherapy remains encapsulated, it does not exert it’s cell-killing effects. Release of the chemotherapy is facilitated by precision delivery of electromagnetic energy to the tissue region harboring remnant cancer cells. In the tissue where this release is triggered, a large chemotherapy dose is released that eliminates the remnant cancer cells.

Screenshot 2024-02-01 102943.png

OncoBLAZE PRECISION THERAPY AFTER SURGERY

Screenshot 2024-02-01 175112.png
Screenshot 2024-02-01 174351.png

By leveraging triggered nanoparticles (TNP) and precision targeting of electromagnetic radiation that triggers chemotherapy release from TNP, we seek to improve outcomes for cancer patients, particularly in cases where traditional methods are insufficient. Our mission is to contribute to the evolution of cancer care, offering promising solutions that address unmet needs in the field. Join us as we work towards a future with improved treatment options for those affected by cancer.

News

 

April 15th 2024:  OncoBLAZE is now a South Carolina Research Association Member Company

We are thrilled to share that OncoBLAZE has officially become a member company of the prestigious South Carolina Research Association (SCRA)! At OncoBLAZE, we are committed to pushing the boundaries of cancer research and technology to improve patient outcomes. Joining SCRA as a member company represents a significant milestone in our journey towards making a tangible difference in the fight against cancer. As a member of SCRA, we gain access to a wealth of resources, expertise, and collaborative opportunities that will further empower us to drive innovation and make meaningful advancements in cancer care. We are incredibly grateful for this opportunity and excited to contribute to the vibrant ecosystem of research and innovation in South Carolina. Thank you to SCRA for welcoming us into this esteemed community. Together, we will continue to push the boundaries of what's possible in cancer research and make a lasting impact on the lives of patients and their families.

Stay tuned for more updates as we embark on this exciting new chapter!

#OncoBLAZE #SCRA #CancerResearch #InnovationInSC

 

March 6th 2024:  Acceptance into the Innosphere Ventures Incubator Program 

We are thrilled to announce that OncoBLAZE has been selected to join the prestigious Innosphere Ventures Incubator Program! At OncoBLAZE, we are dedicated to revolutionizing cancer diagnostics and treatment through cutting-edge technology and innovation. Being accepted into the Innosphere Ventures Incubator Program marks a significant milestone in our journey towards making a meaningful impact in the fight against cancer. As part of the Innosphere Ventures community, we will have access to invaluable resources, mentorship, and networking opportunities that will accelerate our growth and propel us towards success. We are grateful for this opportunity and excited to collaborate with other like-minded entrepreneurs and industry experts. Stay tuned as we continue to advance our mission of transforming cancer care through groundbreaking solutions. Together, we can make a difference. Thank you to everyone who has supported us on this incredible journey!

#OncoBLAZE #InnosphereVentures #CancerInnovation #StartupSuccess

Get in Touch:

OncoBLAZE logo_green DALL-E_v3_transpare
bottom of page